Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth

Molecular and Cellular Endocrinology

Volumn 197, Issue 1-2, 2002, Pages 231-238

  Culig, Zoran ^a   Bartsch, Georg ^a   Hobisch, Alfred ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Androgen receptor; Autocrine and paracrine loops; Interleukin 6; Proliferation; Prostate cancer; Resistance

Indexed keywords

ANDROGEN RECEPTOR; COMPLEMENTARY DNA; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; INTERLEUKIN 6; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE C INHIBITOR;

BASAL CELL; BENIGN TUMOR; CANCER GROWTH; CELL COUNT; CELL PROLIFERATION; DNA TRANSFECTION; GENE EXPRESSION; GROWTH INHIBITION; GROWTH REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; RECEPTOR SENSITIVITY; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; GENETICS; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE; PROSTATE TUMOR; REPORTER GENE;

CELL DIFFERENTIATION; GENES, REPORTER; HUMANS; INTERLEUKIN-6; MALE; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0037195503     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0303-7207(02)00263-0     Document Type: Review

References (64)

1. Abrahamsson P.A. Neuroendocrine differentiation in prostatic carcinoma. Prostate. 39:1999;135-148.
2. Adler H.I., McCurdy M.A., Kaltan M.W., Timme T.L., Scardino P.T., Thompson T.C., Niklinski W.T., Myers C.E., Trepel J.B. Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. J. Urol. 161:1999;182-187.
3. Bang Y.J., Pirnia F., Fang W.G., Kang W.K., Sartor O., Whitesell L., Ha M.J., Tsokos M., Sheahan M.D., Nguyen P. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc. Natl. Acad. Sci. USA. 91:1994;5330-5334.
4. Bellido T., Jilka R.L., Boyce B.F., Girasole G., Broxmeyer H., Dalrymple S.A., Murray R., Manolagas S.C. Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. J. Clin. Invest. 95:1995;2886-2895.
5. Borsellino N., Belldegrun A., Bonavida B. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res. 55:1995;4633-4639.
6. Borsellino N., Bonavida B., Ciliberto G., Toniatti C., Travali S., D'Alessandro N. Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer. 85:1999;134-144.
7. Chen T., Wang L.H., Farrar W.L. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res. 60:2000;2132-2135.
8. Chiu J.J., Sgagias M.K., Covan K.H. Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines. Clin. Cancer Res. 2:1996;215-221.
9. Chung T.D., Yu J.J., Spiotto M.T., Bartkowski M., Simons J.W. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate. 38:1999;199-207.
10. Chung T.D., Yu J.J., Kong T.A., Spiotto M.T., Lin J.M. Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines. Prostate. 42:2000;1-7.
11. Cox M.E., Deeble P.D., Bissonette E.A., Parsons S.J. Activated 3′,5′-cyclic AMP-dependent protein kinase is sufficient to induce neuroendocrine-like differentiation of the LNCaP prostate tumor cell line. J. Biol. Chem. 275:2000;13812-13818.
12. Craft N., Shostak Y., Carey M., Sawyers C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med. 5:1999;280-285.
13. Culig Z., Hobisch A., Cronauer M.V., Radmayr C., Trapman J., Hittmair A., Bartsch G., Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-1, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 54:1994;5474-5478.
14. Culig Z., Hobisch A., Hittmair A., Cronauer M.V., Radmayr C., Zhang J., Bartsch G., Klocker H. Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells. Prostate. 32:1997;106-114.
15. Culig Z., Hoffmann J., Erdel M., Eder I., Hobisch A., Hittmair A., Bartsch G., Utermann G., Schneider M., Parczyk K., Klocker H. Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system. Br. J. Cancer. 81:1999;242-251.
16. Darne C., Veyssiere G., Jean C. Phorbol ester causes ligand-independent activation of the androgen receptor. Eur. J. Biochem. 256:1998;541-549.
17. Degeorges A., Tatoud R., Fauvel Lafeve F., Podgorniak M.P., Millot G., de Cremoux P., Calvo F. Stromal cells from human benign prostate hyperplasia produce a growth-inhibitory factor for LNCaP prostate cancer cells, identified as interleukin-6. Int. J. Cancer. 68:1996;207-214.
18. Florenes V.A., Lu C., Bhattacharya N., Rak J., Sheehan C., Slingerland J.M., Kerbel R.S. Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma. Oncogene. 18:1999;1023-1032.
19. Garcia R., Bowmann T.L., Niu G., Yu H., Minton S., Muro-Cacho C.A., Cox C.E., Falcone R., Fairclough R., Parsons S., Laudano A., Gazit A., Levitzky A., Kraker A., Jove R. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene. 20:2001;2499-2513.
20. Guo Y., Kyprianou N. Overexpression of transforming growth factor-beta1 receptor type II restores transforming growth factor-beta1 sensitivity and signaling in human prostate cancer cells. Cell. Growth Differ. 9:1998;185-193.
21. Hermanns H.M., Radtke S., Schaper F., Heinrich P.C., Behrmann I. Non-redundant signal transduction of interleukin-6-type cytokines. The adapter protein Shc is specifically recruited to the oncostatin M receptor. J. Biol. Chem. 275:2000;40742-40748.
22. Hobisch A., Culig Z., Radmayr C., Bartsch G., Klocker H., Hittmair A. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res. 55:1995;3068-3072.
23. Hobisch A., Culig Z., Radmayr C., Bartsch G., Klocker H., Hittmair A. Androgen receptor status of lymph node metastases from prostate cancer. Prostate. 28:1996;129-135.
24. Hobisch A., Eder I.E., Putz T., Horninger W., Bartsch G., Klocker H., Culig Z. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. 58:1998;4640-4645.
25. Hobisch A., Rogatsch H., Hittmair A., Fuchs D., Bartsch G. Jr., Klocker H., Bartsch G., Culig Z. Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J. Pathol. 191:2000;239-244.
26. Hobisch A., Ramoner R., Fuchs D., Godoy-Tundidor S., Bartsch G., Klocker H., Culig Z. Prostate cancer cells (LNCaP) generated after long-term interleukin-6 treatment express interleukin-6 and acquire an interleukin-6-partially resistant phenotype. Clin. Cancer Res. 7:2001;2941-2948.
27. Hoosein N., Abdul M., McCabe R., Gero E., Deftos L., Banks M., Hodges S., Finn L., Logothetis C. Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer. Urol. Oncol. 1:1995;246-251.
28. Huggins C., Hodges C.V. Studies on prostatic cancer: the effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1:1941;293-297.
29. Ischia R., Culig Z., Eder U., Bartsch G., Winkler H., Fischer-Colbrie R., Klocker H. Presence of chromogranins and regulation of their synthesis and processing in a neuroendocrine prostate tumor cell line. Prostate. S8:1998;80-87.
30. Ischia R., Hobisch A., Bauer R., Weiss U., Gasser R.W., Horninger W., Bartsch G. Jr., Fuchs D., Bartsch G., Winkler H., Klocker H., Fischer-Colbrie R., Culig Z. Elevated levels of serum secretoneurin in patients with therapy resistant carcinoma of the prostate. J. Urol. 163:2000;1161-1165.
31. Jones S.A., Horiuchi S., Topley N., Yamanoto N., Fuller G.M. The soluble interleukin 6 receptor: mechanism of production and implications in disease. FASEB J. 15:2001;43-58.
32. Junicho A., Matsuda T., Yamamoto T., Kishi H., Korkmaz K., Saatcioglu F., Fuse H., Muraguchi A. Protein inhibitor of activated STAT3 regulates androgen receptor signaling in prostate carcinoma cells. Biochem. Biophys. Res. Commun. 278:2000;9-13.
33. Kim I.Y., Kim J.H., Zelner D.J., Ahn H.J., Sensibar J.A., Lee C. Transforming growth factor-beta1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP. Endocrinology. 137:1996;991-999.
34. Kim I.Y., Ahn H.J., Zelner D.J., Shaw J.W., Sensibar J.A., Kim J.H., Kato M., Lee C. Genetic change in transforming growth factor beta (TGF-beta) receptor type I gene correlates with insensitivity to TGF-beta 1 in human prostate cancer cells. Cancer Res. 56:1996;44-48.
35. Kokontis J., Takakura K., Hay N., Liao S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res. 54:1994;1566-1573.
36. Kube D., Holtick U., Vockerodt M., Ahmadi T., Haier B., Behrmann I., Heinrich P.C., Diehl V., Tesch H. STAT3 is constitutively activated in Hodgin cell lines. Blood. 98:2001;762-770.
37. Levesque E., Beaulieu M., Guillemette C., Hum D.W., Belanger A. Effect of interleukins on UGT2B15 and UGT2B17 steroid uridine diphosphate-glucuronosyltransferase expression and activity in the LNCaP cell line. Endocrinology. 139:1998;2375-2381.
38. Lin D.L., Whitney M.C., Yao Z., Keller E.T. Interleukin-6 induces androgen responsiveness in prostate cancer cells through up-regulation of androgen receptor expression. Clin. Cancer Res. 7:2001;1773-1781.
39. Lou W., Ni Z., Dyer K., Tweardy D.J., Gao A.C. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate. 42:2000;239-242.
40. Lu C., Sheehan C., Rak J.W., Chambers C.A., Hozumi N., Kerbal R.S. Endogenous interleukin-6 can function as an in vivo growth-stimulatory factor for advanced-stage human melanoma cells. Clin. Cancer Res. 2:1996;1417-1425.
41. Lu C., Vickers M.F., Kerbel R.S. Interleukin-6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc. Natl. Acad. Sci. USA. 89:1992;9215-9219.
42. Matsuda T., Junicho A., Yamamoto T., Kishi H., Korkmaz K., Saatcioglu F., Fuse H., Muraguchi A. Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells. Biochem. Biophys. Res. Commun. 283:2001;179-187.
43. Mori S., Murakami-Mori K., Bonavida B. Interleukin-6 induces G1 arrest through induction of p27 (Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells. Biochem. Biophys. Res. Commun. 257:1999;609-614.
44. Nakashima J., Tachibana M., Horiguchi Y., Oya M., Ohigashi T., Asakura H., Murai M. Serum interleukin-6 as a prognostic factor in patients with prostate cancer. Clin. Cancer Res. 6:2000;2702-2706.
45. Nazareth L.V., Weigel N.L. Activation of the human androgen receptor through a protein kinase A signaling pathway. J. Biol. Chem. 271:1996;19900-19907.
46. Noordzij M.A., van Weerden W.M., de Ridder C.M., van der Kwast T.H., Schroder F.H., ven Steenbrugge G.J. Neuroendocrine differentiation in human prostatic tumor models. Am. J. Pathol. 149:1996;859-871.
47. Okamoto M., Lee C., Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res. 57:1997;141-146.
48. Okamoto M., Lee C., Oyasu R. Autocrine effect of androgen on proliferation of an androgen-responsive prostatic carcinoma cell line, LNCaP: role of interleukin-6. Endocrinology. 138:1997;5071-5074.
49. Petrucci M.T., Ricciardi M.R., Ariola C., Gregori C., Ribersani M., Savino R., Ciliberto G., Tafuri A. Cell cycle regulation and induction of apoptosis by interleukin-6 variants on the multiple myeloma cell line XG-1. Ann. Hematol. 78:1999;13-18.
50. Qiu Y., Ravi L., Kung H.-J. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature. 393:1998;83-85.
51. Qiu Y., Robinson D., Pretlow T.G., Kung H.-J. Etx/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3′-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc. Natl. Acad. Sci. USA. 95:1998;3644-3649.
52. Sadar M.D., Gleave M.E. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Cancer Res. 60:2000;5825-5831.
53. Sadi M.V., Walsh P.C., Barrack E.R. Immunohistochemical study of androgen receptors in metastatic prostate cancer-comparison of receptor content and response to hormonal therapy. Cancer. 67:1991;3057-3064.
54. Schaefer L.K., Menter D.G., Schaefer T.S. Activation of stat3 and stat1 DNA binding and transcriptional activity in human brain tumour cell lines by gp130 cytokines. Cell. Signal. 12:2000;143-151.
55. Silvani A., Ferrari G., Paonessa G., Toniatti C., Parmiani G., Colombo M.P. Down-regulation of interleukin 6 receptor alpha chain in interleukin 6 transduced melanoma cells causes selective resistance to interleukin 6 but not oncostatin M. Cancer Res. 55:1995;2200-2205.
56. Speirs V., Kerin M.J., Walton D.S., Newton C.J., Desai S.B., Atkin S.L. Direct activation of oestrogen receptor-alpha by interleukin-6 in primary cultures of breast cancer epithelial cells. Br. J. Cancer. 82:2000;1312-1316.
57. Spiotto M.T., Chung T.D. STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate. 42:2000;88-98.
58. Spiotto M.T., Chung T.D. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate. 42:2000;186-195.
59. Takeda T., Kurachi H., Yamamoto H., Nishio Y., Nakatsuji Y., Morishige K.I., Miyake A., Murata A. Crosstalk between the interleukin-6 (IL-6)-JAK-STAT and the glucocorticoid-nuclear receptor pathway: synergistic activation of IL-6 response element by IL-6 and glucocorticoid. J. Endocrinol. 159:1998;323-330.
60. Twillie D.A., Eisenberger M.A., Carducci M.A., Hseih W.S., Kim W.Y., Simons J.W. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology. 45:1995;542-549.
61. Van der Kwast T.H., Schalken J., Ruizeveld de Winter J.A., van Vroonhoven C.C.J., Mulder E., Boersma W., Trapman J. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int. J. Cancer. 48:1991;189-193.
62. Veldscholte J., Ris-Stalpers C., Kuiper G.G.J.M., Jenster G., Berrevoets C., Claassen E., van Rooij H.C.J., Trapman J., Brinkmann A.O. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun. 17:1990;534-540.
63. Zelivianski S., Verni M., Moore C., Kondrikov D., Taylor R., Lin M.F. Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype. Biochim. Biophys. Acta. 1539:2001;28-43.
64. Zhang Z., Jones S., Hagood J.S., Fuentes N.L., Fuller G.M. STAT3 acts as a coactivator of glucocorticoid receptor signaling. J. Biol. Chem. 272:1997;30607-30610.